FISH Equivocal HER2 ERBB2 Test: Advanced Genetic Analysis for Breast Cancer
Comprehensive Introduction to HER2 Genetic Testing
The FISH Equivocal HER2 ERBB2 Test represents a critical advancement in precision oncology, specifically designed to resolve ambiguous HER2 status in breast cancer diagnosis. When traditional immunohistochemistry (IHC) testing yields uncertain or borderline results, this sophisticated genetic analysis provides definitive clarity. The ERBB2 gene, commonly known as HER2, plays a pivotal role in cancer cell growth and proliferation, making accurate detection essential for targeted treatment planning.
This specialized test utilizes Fluorescence In Situ Hybridization (FISH) technology to directly visualize gene amplification at the molecular level. By providing unambiguous results, it eliminates the uncertainty that can delay critical treatment decisions and ensures patients receive the most appropriate therapeutic interventions based on their specific genetic profile.
What the FISH Equivocal HER2 ERBB2 Test Measures
This advanced diagnostic test specifically detects and quantifies:
- ERBB2 Gene Amplification: Direct measurement of HER2 gene copy numbers in cancer cells
- Chromosome 17 Status: Analysis of chromosome 17 polysomy to ensure accurate interpretation
- HER2/CEP17 Ratio: Precise calculation of the ratio between HER2 signals and chromosome 17 centromere signals
- Genetic Abnormalities: Identification of specific genetic alterations affecting HER2 expression
Who Should Consider This Test
This specialized genetic analysis is recommended for patients with:
- Borderline or equivocal HER2 results from initial IHC testing
- Invasive breast cancer requiring definitive HER2 status determination
- Recurrent breast cancer with ambiguous HER2 expression
- Metastatic breast cancer where targeted therapy decisions depend on HER2 status
- Cases where treatment with HER2-targeted therapies (like trastuzumab) is being considered
Significant Benefits of FISH Equivocal HER2 Testing
- Treatment Precision: Enables accurate selection of HER2-targeted therapies
- Reduced Uncertainty: Eliminates ambiguity in treatment decision-making
- Personalized Care: Facilitates tailored treatment plans based on genetic profile
- Improved Outcomes: Increases likelihood of successful treatment response
- Comprehensive Analysis: Provides detailed genetic information beyond standard testing
Understanding Your Test Results
Your FISH Equivocal HER2 ERBB2 Test results will provide clear classification:
- HER2 Positive: Indicates gene amplification, making you eligible for HER2-targeted therapies
- HER2 Negative: Confirms absence of gene amplification, guiding alternative treatment strategies
- Detailed Report: Includes comprehensive analysis of genetic markers and clinical implications
- Expert Interpretation: Results are reviewed by board-certified genetic specialists
Test Pricing Information
| Price Type | Amount (USD) |
|---|---|
| Discount Price | $322 |
| Regular Price | $358 |
Nationwide Testing Availability
We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified laboratories ensures consistent, high-quality testing standards nationwide.
Take Action for Your Health
Don’t let uncertainty delay your cancer treatment decisions. The FISH Equivocal HER2 ERBB2 Test provides the definitive answers you need to move forward with confidence. Our team of genetic specialists is ready to assist you with comprehensive testing and personalized support.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your FISH Equivocal HER2 ERBB2 Test and take the next step toward personalized cancer care.
With a rapid one-week turnaround time and comprehensive genetic analysis, this test represents a crucial tool in modern oncology. Trust our expertise in cytogenetics to provide the accurate, reliable results that can make a significant difference in your treatment journey.
